Pharmaceutical Market Europe (PME)

PME is a monthly print and digital title written by experienced journalists and high-profile pharma and healthcare experts. The magazine provides insights and offers solutions to the issues that keep industry leaders awake at night.

From the latest developments in cancer treatments and the strategies behind them to new marketing and commercialisation models and the regulations that underpin the fabric of the sector – PME's got it covered.

PME is a trusted source for decision makers and influencers in pharma and healthcare who, through the practical and accessible content, have the knowledge to tackle whatever comes their way.

From: Research

Novartis eyes potential new indication for Cosentyx

Novartis HQUnveils positive late-stage results in axial spondyloarthritis

From: Research

Acceleron scraps rare muscular dystrophy drug

AcceleronClinical profile not strong enough to push into late-stage testing

From: Regulatory

J&J's Tremfya filed for approval in US for psoriatic arthritis

Seeking share of increasingly competitive psoriasis market

From: Research

New data backs GeNeuro’s MS drug after Servier exit

Brain scanSearch continues for new development partner


Pharmaceutical Market Europe - September 2019

Patient vs Pharma, this is the situation which the industry dreads, but in 2019 has become a reality on several fronts: when patients see pharma not as a friend, but a foe.

Pharmaceutical Market Europe (PME) magazine is also available on the iPhone/iPad as a free app

Editor - Iona Everson

Have your say...

AZ shares spike on good second quarter led by cancer drugs

Soriot expecting no fewer than five of AZ’s new drugs to hit blockbuster status this year

AstraZeneca AZ

'Nothing about us without us'

Why patient engagement is essential throughout the entire product life cycle

Meike Wenzel

Edging Evolution

You don’t have to wait for your business to evolve

darwins medicine